Indivior (INDV) said Wednesday that the US Food and Drug Administration has delayed its decision on the marketing application for label changes to Sublocade Injection.
Indivior said the FDA has no outstanding issues to address, adding that the company will provide additional updates on the approval status of the proposed label changes as needed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.